BOSTON, May 28, 2025 -- Aktis Oncology, Inc., an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced...
MethylGene and Pharmion report preliminary clinical data at the 2007 AACR-NCI-EORTC International Conference
News | 10. 24. 2007
MethylGene Inc. (TSX:MYG) and Pharmion Corporation (NASDAQ:PHRM) today reported preliminary clinical data from the Companies' MGCD0103 Phase I/II combination trial with Gemzar® (Trial 006). The data were presented in a poster session at the 2007 AACR-NCI- EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco on October 24th, 2007.
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.